Bank of America Corp DE bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 413,145 shares of the company's stock, valued at approximately $4,260,000. Bank of America Corp DE owned 0.58% of Immix Biopharma at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of IMMX. Legal & General Group Plc bought a new stake in shares of Immix Biopharma during the second quarter worth $41,000. Compass Financial Management LLC acquired a new position in Immix Biopharma in the 2nd quarter worth $56,000. Allworth Financial LP bought a new position in Immix Biopharma during the 2nd quarter worth about $75,000. Everhart Financial Group Inc. acquired a new stake in shares of Immix Biopharma in the 2nd quarter valued at about $103,000. Finally, Kera Capital Partners Inc. acquired a new stake in shares of Immix Biopharma in the 4th quarter valued at about $68,000. Institutional investors and hedge funds own 11.26% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently issued reports on IMMX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immix Biopharma in a report on Friday, July 17th. Lifesci Capital assumed coverage on shares of Immix Biopharma in a research note on Wednesday, June 17th. They set an "outperform" rating and a $19.00 price target for the company. Bank of America started coverage on shares of Immix Biopharma in a research report on Thursday, June 18th. They issued a "buy" rating and a $27.00 price objective on the stock. Mizuho raised their target price on shares of Immix Biopharma from $15.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, September 15th. Finally, Needham & Company LLC began coverage on shares of Immix Biopharma in a research note on Wednesday, July 22nd. They issued a "buy" rating and a $21.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.86.
Check Out Our Latest Research Report on Immix Biopharma
Immix Biopharma Stock Performance
Immix Biopharma stock opened at $11.47 on Tuesday. The stock has a 50-day simple moving average of $11.62 and a 200 day simple moving average of $10.23. The stock has a market capitalization of $820.56 million, a P/E ratio of -13.03 and a beta of 0.20. Immix Biopharma, Inc. has a 52 week low of $1.99 and a 52 week high of $15.10.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Research analysts forecast that Immix Biopharma, Inc. will post -0.73 earnings per share for the current year.
About Immix Biopharma
(
Free Report)
Immix Biopharma, Inc NASDAQ: IMMX is a clinical-stage biopharmaceutical company developing cell therapies for cancer and autoimmune diseases. The company focuses on treatments designed to target disease-associated cells and address serious conditions with limited therapeutic options.
Its lead product candidate is NXC-201, an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA). NXC-201 is being investigated for relapsed or refractory AL amyloidosis and multiple myeloma, two diseases involving abnormal plasma cells.
See Also
Want to see what other hedge funds are holding IMMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
